NervGen Pharma Corp (NGEN)

[tootalljones]

"The annual stroke market is valued at over USD 37 billion1. The global stroke diagnostic and therapeutic market size is predicted to hit over USD 71.96 billion by 2032, growing at a CAGR of 8% during the forecast period 2023 to 20322."
Learn more:
https://nervgen.com/nervgen-pharmas-nvg-291-r-demonstrates-significant-functional-repair-from-a-stroke-7-days-after-onset-in-landmark-preclinical-study-by-university-of-cincinnati-and-case-western-reserve-univer/

"
The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset
There is currently no FDA-approved drug for the repair of damage from a stroke
NVG-291, currently in a Phase 1 clinical trial in healthy human subjects, could provide a completely new treatment paradigm for stroke patients"

https://nervgen.com/nervgen-pharmas-nvg-291-r-demonstrates-significant-functional-repair-from-a-stroke-7-days-after-onset-in-landmark-preclinical-study-by-university-of-cincinnati-and-case-western-reserve-univer/
"Vancouver, Canada July 28, 2022 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce......"